An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress

Sarcoglycanopathies are rare autosomic limb girdle muscular dystrophies caused by mutations in one of the genes coding for sarcoglycans. Sarcoglycans form a complex, which is an important part of the dystrophin-associated glycoprotein complex and which protects the sarcolemma against muscle contract...

Full description

Bibliographic Details
Main Authors: David Israeli, Jérémie Cosette, Guillaume Corre, Fatima Amor, Jérôme Poupiot, Daniel Stockholm, Marie Montus, Bernard Gjata, Isabelle Richard
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050119300439
id doaj-ee8e06cdf9eb4628b70c764a33633dd6
record_format Article
spelling doaj-ee8e06cdf9eb4628b70c764a33633dd62020-11-25T01:09:10ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012019-06-0113494502An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical StressDavid Israeli0Jérémie Cosette1Guillaume Corre2Fatima Amor3Jérôme Poupiot4Daniel Stockholm5Marie Montus6Bernard Gjata7Isabelle Richard8INTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, FranceINTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 91002 Evry, France; Corresponding author: Isabelle Richard, INTEGRARE, Généthon, INSERM, Université Evry, Université Paris-Saclay, 1 rue de l’Internationale, 91000 Evry, France.Sarcoglycanopathies are rare autosomic limb girdle muscular dystrophies caused by mutations in one of the genes coding for sarcoglycans. Sarcoglycans form a complex, which is an important part of the dystrophin-associated glycoprotein complex and which protects the sarcolemma against muscle contraction-induced damage. Absence of one of the sarcoglycans on the plasma membrane reduces the stability of the whole complex and perturbs muscle fiber membrane integrity. There is currently no curative treatment for any of the sarcoglycanopathies. A first clinical trial to evaluate the safety of a recombinant AAV2/1 vector expressing γ-sarcoglycan using an intramuscular route of administration showed limited expression of the transgene and good tolerance of the approach. In this report, we undertook a dose-effect study in mice to evaluate the efficiency of an AAV2/8-expressing γ-sarcoglycan controlled by a muscle-specific promoter with a systemic mode of administration. We observed a dose-related efficiency with a nearly complete restoration of gamma sarcoglycan (SGCG) expression, histological appearance, biomarker level, and whole-body strength at the highest dose tested. In addition, our data suggest that a high expression threshold level must be achieved for effective protection of the transduced muscle, while a suboptimal transgene expression level might be less protective in the context of mechanical stress. Keywords: LGMD2C, γ-sarcoglycanopathy, limb girdle muscular dystrophy, gene therapy, translational medicine, AAV, miRNA biomarker, mechanical stresshttp://www.sciencedirect.com/science/article/pii/S2329050119300439
collection DOAJ
language English
format Article
sources DOAJ
author David Israeli
Jérémie Cosette
Guillaume Corre
Fatima Amor
Jérôme Poupiot
Daniel Stockholm
Marie Montus
Bernard Gjata
Isabelle Richard
spellingShingle David Israeli
Jérémie Cosette
Guillaume Corre
Fatima Amor
Jérôme Poupiot
Daniel Stockholm
Marie Montus
Bernard Gjata
Isabelle Richard
An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
Molecular Therapy: Methods & Clinical Development
author_facet David Israeli
Jérémie Cosette
Guillaume Corre
Fatima Amor
Jérôme Poupiot
Daniel Stockholm
Marie Montus
Bernard Gjata
Isabelle Richard
author_sort David Israeli
title An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
title_short An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
title_full An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
title_fullStr An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
title_full_unstemmed An AAV-SGCG Dose-Response Study in a γ-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress
title_sort aav-sgcg dose-response study in a γ-sarcoglycanopathy mouse model in the context of mechanical stress
publisher Elsevier
series Molecular Therapy: Methods & Clinical Development
issn 2329-0501
publishDate 2019-06-01
description Sarcoglycanopathies are rare autosomic limb girdle muscular dystrophies caused by mutations in one of the genes coding for sarcoglycans. Sarcoglycans form a complex, which is an important part of the dystrophin-associated glycoprotein complex and which protects the sarcolemma against muscle contraction-induced damage. Absence of one of the sarcoglycans on the plasma membrane reduces the stability of the whole complex and perturbs muscle fiber membrane integrity. There is currently no curative treatment for any of the sarcoglycanopathies. A first clinical trial to evaluate the safety of a recombinant AAV2/1 vector expressing γ-sarcoglycan using an intramuscular route of administration showed limited expression of the transgene and good tolerance of the approach. In this report, we undertook a dose-effect study in mice to evaluate the efficiency of an AAV2/8-expressing γ-sarcoglycan controlled by a muscle-specific promoter with a systemic mode of administration. We observed a dose-related efficiency with a nearly complete restoration of gamma sarcoglycan (SGCG) expression, histological appearance, biomarker level, and whole-body strength at the highest dose tested. In addition, our data suggest that a high expression threshold level must be achieved for effective protection of the transduced muscle, while a suboptimal transgene expression level might be less protective in the context of mechanical stress. Keywords: LGMD2C, γ-sarcoglycanopathy, limb girdle muscular dystrophy, gene therapy, translational medicine, AAV, miRNA biomarker, mechanical stress
url http://www.sciencedirect.com/science/article/pii/S2329050119300439
work_keys_str_mv AT davidisraeli anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT jeremiecosette anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT guillaumecorre anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT fatimaamor anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT jeromepoupiot anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT danielstockholm anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT mariemontus anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT bernardgjata anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT isabellerichard anaavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT davidisraeli aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT jeremiecosette aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT guillaumecorre aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT fatimaamor aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT jeromepoupiot aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT danielstockholm aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT mariemontus aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT bernardgjata aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
AT isabellerichard aavsgcgdoseresponsestudyinagsarcoglycanopathymousemodelinthecontextofmechanicalstress
_version_ 1725179679599493120